Cargando…

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

Immune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have revolutionized the treatment of cancer but are only efficacious in a small subset of patients. Targeting suppressive mechanisms acting on innate immune cells could significantly improve the incidence of clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dowling, John P., Nikitin, Pavel A., Shen, Fang, Shukla, Halley, Finn, James P., Patel, Nirja, Swider, Cezary, Bingaman-Steele, Jamie L., Nicolescu, Chris, Sikorski, Eden L, Greenawalt, Evan J., Morin, Michael J., Robinson, Matthew K., Lundgren, Karen, Harman, Benjamin C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208126/ https://www.ncbi.nlm.nih.gov/pubmed/37216961 http://dx.doi.org/10.1080/19420862.2023.2212673

Ejemplares similares

Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein
por: DiMuzio, Jillian M., et al.
Publicado: (2021)

IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
por: Nikitin, Pavel A., et al.
Publicado: (2022)

Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade
por: Kwong, Tsz Tung, et al.
Publicado: (2020)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis
por: Choi, Yeon-Sook, et al.
Publicado: (2022)

Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy
por: Zhang, Chi, et al.
Publicado: (2018)

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
Publicado: (1990)

Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity
Publicado: (1989)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity
por: Nawaf, Maher G., et al.
Publicado: (2017)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade
por: Kang, Wenyi, et al.
Publicado: (2022)

Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells
por: Wang, Tingting, et al.
Publicado: (2019)

The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade
por: Park, Jang Hyun, et al.
Publicado: (2022)

Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer
por: Feng, Mei, et al.
Publicado: (2023)

Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression
por: AbuEid, Mahmoud, et al.
Publicado: (2021)

Targeting phosphatidylserine synergizes with immune checkpoint blockade by inducing de novo tumor specific immunity
por: Huang, Xianming, et al.
Publicado: (2015)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
por: Andersson, Patrik, et al.
Publicado: (2019)

The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer
por: Liu, Xiangzheng, et al.
Publicado: (2021)

Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy
por: Subramanian, Madhav, et al.
Publicado: (2023)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
por: Peng, Zhi-Peng, et al.
Publicado: (2023)

Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal anti-tumor immunity
por: Choi, Yongbin, et al.
Publicado: (2023)

Role of tumor gene mutations in treatment response to immune checkpoint blockades
por: Wang, Manni, et al.
Publicado: (2019)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
por: Arrieta, Víctor A., et al.
Publicado: (2023)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
por: Liu, Yuying, et al.
Publicado: (2017)

PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease
por: Duhalde Vega, Maite, et al.
Publicado: (2022)

Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity
por: Scherwitzl, Iris, et al.
Publicado: (2018)

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
por: Anagnostou, Valsamo, et al.
Publicado: (2020)

Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
por: Pingili, Ajeeth K., et al.
Publicado: (2021)

Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune “cold” tumors
por: Xiao, Guixiu, et al.
Publicado: (2023)

Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer
por: Guo, Jhe‐Cyuan, et al.
Publicado: (2023)

Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence
por: Ananth, Abhirami A., et al.
Publicado: (2016)

ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
por: Lee, Yu-Hung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3jenr9nsm7d2bo0c6i5nu98iv1